CEO says Moderna Booster Shot to Be Ready by Late Summer/Early Fall

 

On April 23, Moderna CEO Stephane Bancel said that the Moderna booster shot would be available by late summer or early fall. He said this at an International Federation of Pharmaceutical Manufacturers and Associations briefing.

 

The Moderna vaccine, like the Pfizer/BioNtech vaccine is a two dose vaccine. It is said that immunity stays for about six months after the second dose. However, the vaccine has not been as effective with the variants of the coronavirus, as was hoped for. So, the company is developing a booster shot which would tackle the strains, mainly the South Africa strain.

 

 

Moderna is researching on two booster vaccines one of which is specifically targeting the B.1.351 variant, commonly known as the South Africa variant while the second booster dose will be a multivalent booster vaccine.

 

The CEO also said that research has been promising and clinical trials are moving along at a good pace. Bancel also said that it might even be possible to launch the booster shot by late summer or early fall.

 

Earlier, on April 14, when Bancel spoke to CNBC’s Squawk Box, the company was looking to develop a future booster shot that would target both COVID-19 and the flu, so users could get one shot in future. He also said that they were working towards a more effective flu shot, so that one shot would give user immunity against two common infections: the flu and coronavirus.

 

MRNA

 

Earlier, on April 13, Moderna released research carried out on its current two-dose vaccines from phase three clinical trials. The regulations indicated that the vaccine is highly effective even after six months after the second dose. It has an above 90 percent efficacy against symptomatic COVID-19 for six months. It is also above 95 percent effective against severe COVID-19 up to six months after the second dose.

 

The trials also show that only about 900 cases of COVID-19 were reported after almost 132 million doses of Moderna were delivered all over the world. Only 100 cases were reported to be severe among the vaccinated participants at the trial period through April 9.

 

Both the Pfizer and Moderna booster shots have shown promise and both the companies believe that they would deliver these shots by fall.


Follow us on Google news for more updates and News










PLEASE READ THE IMPORTANT DISCLOSURES BELOW.

This content is being provided to you for informational purposes only. The content has been prepared by third parties not affiliated with CWEB Inc, a business. This content and any information contained therein, does not constitute a recommendation by CWEB to buy, sell or hold any security, financial product or instrument referenced in the content. This information neither is, nor should be construed as an offer, or a solicitation of an offer, to buy or sell securities by CWEB Inc. CWEB Inc. does not offer or provide any opinion regarding the nature, potential, value, suitability or profitability of any particular investment or investment strategy, and you shall be fully responsible for any investment decisions you make, and such decisions will be based solely on your evaluation of your financial circumstances, investment objectives, risk tolerance, and liquidity needs.

Unless stated otherwise, the web content provided by the CWEB family of companies is for educational purposes only. The information and tools provided neither are, nor should be construed, as an offer, or a solicitation of an offer, to buy or sell securities by CWEB Inc. or its affiliates. Unless stated otherwise, no information presented constitutes a recommendation by CWEB Inc. or its affiliates to buy, sell or hold any security, financial product or instrument discussed therein or to engage in any specific investment strategy.

Full Disclaimer


>